Orapin EnkvetchakulOnsiri ThanathaneeRam RangsinKaevalin LekhanontOlan Suwan-ApichonKhon Kaen UniversityPhramongkutklao College of MedicineMahidol University2018-05-032018-05-032011-11-01Cornea. Vol.30, No.11 (2011), 1213-121815364798027737402-s2.0-80053621316https://repository.li.mahidol.ac.th/handle/20.500.14594/12245Purpose: To evaluate the efficacy and safety of intralesional injection of bevacizumab on primary pterygium treatment. Methods: In this randomized controlled trial, each primary pterygium patient was randomized to receive either an intralesional injection of bevacizumab 2 mg (1 mg/0.04 mL) or a combination of topical antihistamine (antazoline HCl 0.05%) and vasoconstrictor (tetrahydrozoline HCl 0.04%) as a control. The main outcome measurements were symptoms and signs (including eye irritation, epiphora, redness, amount of discharge, inflammation and elevation of pterygium, and percentage of corneal pterygium area). Results: A total of 74 pterygium eyes in 66 patients were randomized and allocated into a treatment group (N = 34) and a control group (N = 40). In the treatment group, there was a statistically significant reduction of symptoms (including irritation, photophobia, epiphora, redness, discharge, and blurred vision) and signs (inflammation and corneal pterygium area) compared with the baseline, up to at least 6 months. Between the treatment and control groups, no significant differences were found for all visits with respect to the (1) symptoms, (2) signs, and (3) percentage of corneal pterygium. Conclusions: Intralesional bevacizumab may have a therapeutic effect on symptoms and signs of primary pterygium for at least 6 months (ie, the follow-up period), with no serious ocular or systemic adverse effects. Copyright © 2011 by Lippincott Williams & Wilkins.Mahidol UniversityMedicineArticleSCOPUS10.1097/ICO.0b013e31821c9b44